Shionogi & Co. Ltd.'s novel influenza drug Xofluza (baloxavir marboxil) has met its primary endpoint in a Phase III trial which looked at its ability to halt symptoms in people already exposed to the virus, setting the stage for a Japanese approval filing in this setting.
The Phase III, double-blind BLOCKSTONE study in Japan showed a clear prophylactic effect after a single oral dose, which significantly...







